Hogan Lovells advises Jennewein Biotechnologie GmbH on its capital increase

Press releases | 26 March 2020

Led by Frankfurt-based partner Prof. Dr. Michael Schlitt, international law firm Hogan Lovells has advised Jennewein Biotechnologie GmbH on its capital increase. The capital increase was executed with the participation of existing investors.

Jennewein Biotechnologie is a science-based company in the field of industrial biotechnology and is specialized in the development of new production processes for scarce functional sugars. Human milk oligosaccharides (HMOs) represent one of the Company's major fields of activity. These are complex sugar molecules that, in nature, are found uniquely in human milk.

Hogan Lovells Team for Jennewein Biotechnologie GmbH

Prof. Dr. Michael Schlitt (Partner, Lead), Peter Huber (Partner), Dr. Susanne Ries (Of Counsel), Mark Devlin (Counsel), Dr. Timo Lockemann, Christian Schröder, Kilian Pfahl (Associates) (all Corporate);

Eva-Christina Sommer (Business Lawyer), Andreas Mildner (Research Assistant) (all Capital Markets).